MedTrace Logo

Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls

NCT01173900 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5532

Last updated 2011-11-08

No results posted yet for this study

Summary

The aims of this study are:

1. To determine feasibility of a school-based human papillomavirus (HPV) vaccination programme in Tanzania.
2. To measure the uptake and acceptability of two different vaccination strategies in rural and urban schools.
3. To examine the characteristics of accepters/refusers of vaccination and to identify reasons for acceptance, refusal or non-completion.
4. To measure the cost of implementing a school-based HPV vaccination programme in Tanzania.

Conditions

Interventions

BIOLOGICAL

Gardasil® HPV vaccine

0.5 ml given at 0, 2, 6 months

Sponsors & Collaborators

  • National Institute for Medical Research, Tanzania

    collaborator OTHER_GOV

  • Ocean Road Cancer Institute, Tanzania

    collaborator UNKNOWN

  • Institut Català d' Oncologia, Spain

    collaborator UNKNOWN

  • Medical Research Council Social & Public Health Sciences Unit, UK

    collaborator UNKNOWN

  • International Union Against Cancer, Switzerland

    collaborator UNKNOWN

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Deborah :L Watson-Jones, MD, PhD · London School of Hygiene and Tropical Medicine

  • Richard J Hayes, DSC · London School of Hygiene and Tropical Medicine

  • John Changalucha, BSc · National Institute for Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173900 on ClinicalTrials.gov